Last reviewed · How we verify
RILMENIDINE
Rilmenidine is a marketed drug with its key composition patent expiring in 2028, positioning it as an established therapy in its therapeutic area. The drug's key strength lies in its current market presence, leveraging its approved status and ongoing revenue generation. The primary risk is the patent expiry in 2028, which could lead to increased competition from generics.
At a glance
| Generic name | RILMENIDINE |
|---|---|
| Modality | Small molecule |
| Phase | FDA-approved |
| First approval | 1987 |
Approved indications
Common side effects
Key clinical trials
- Renal Artery Stenting in Patients With Documented Resistant Hypertension and Atherosclerotic Renal Artery Stenosis (ANDORRA) (PHASE4)
- Sympathetic Nerve Activity in Renal Failure (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| FDA label | Mechanism, indications, dosing, boxed warnings, drug interactions |
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- RILMENIDINE CI brief — competitive landscape report
- RILMENIDINE updates RSS · CI watch RSS